Company: 

Orchard Therapeutics

Orchard Therapeutics plc

Niche played a pivotal role in the successful registration of Strimvelis, the world’s first ex vivo autologous gene therapy to gain regulatory approval. As a trusted partner in this landmark achievement, we provided critical expertise in regulatory strategy, data integration and preparation of the clinical and technical documentation that met the rigorous standards of the European Medicines Agency. Our deep understanding of the complexities surrounding advanced therapy medicinal products (ATMPs), was instrumental in securing the historic approval of Strimvelis for ADA-SCID.

Following the acquisition of Strimvelis and associated gene therapy assets by Orchard Therapeutics, our contributions were formally acknowledged as foundational to the success of the regulatory submission. Our involvement included:

  • General regulatory, editorial and medical writing support
  • Clinical study protocols and study reports
  • Investigator’s brochure and CTA submission documents
  • Patient narratives
  • Agency submission (MAA/NDA) documents

What our client said

"I have always been impressed by the standard of the work delivered by the Niche teams. In addition, the contracting process is simple and efficient, communication is open, frequent and proactive, with any issues getting resolved quickly and efficiently.."

photophotophotophotophoto

Dr Alan Richardson, Senior Director

Orchard Tx




Request copy of the testimonial
Project background
Orchard Therapeutics is a London-based biotech company focused on developing gene therapies, based on autologous hematopoietic stem cells, to treat rare diseases. Although a relatively recent company founded in 2015, their heritage goes back to some of the earliest gene therapy research. Their ex vivo autologous approach involves inserting a working copy of a missing or faulty gene into a patient’s own haematopoietic stem cells and infusing these back into the patient. This aims to permanently correct genetic disorders with a single treatment.
Delivery

Being a small biotech company, Orchard focuses on key competencies internally, while engaging with bespoke service providers to deliver important aspects of their business. Niche has helped Orchard with this agile business model over several years, by generating submission-ready regulatory documents such as clinical study reports for Orchard’s HSC-based gene therapies. This ongoing collaboration underscores our proven track record in navigating the unique regulatory and clinical challenges of gene therapy development and our shared dedication to bringing transformative treatments to patients with rare and life-threatening diseases.

From the outset, Niche's expertise aligned well with Orchard's streamlined approach to operations. Our contracting process is simple and efficient, allowing both Orchard and Niche to focus on what’s important – clinical development of pioneering gene therapies. Frequent, open, proactive communication enabled operational efficiency. Moreover, deliverables are generated according to tight regulatory timelines. The Niche team is passionate and dedicated, with extensive in-house knowledge of gene therapy. This combination of efficiency and expertise has helped Orchard to drive forward the gene therapy specialism, one of the most revolutionary fields in biotechnology.

Related Case studies

Erytech Pharma SA

Regulatory Affairs

Erytech Pharma is a clinical-stage biopharmaceutical company best known for its proprietary ERYCAPS® red cell encapsulation platform

Niche partnered with Erytech Pharma to rescue and rewrite substandard clinical study reports, delivering a high-quality.

read more

DemeRx

Regulatory Affairs

DemeRx is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction.

Niche provided DemeRx with end-to-end support to launch a pioneering ibogaine addiction trial, covering site.

read more

EVERSANA

Regulatory Affairs

EVERSANA is a leading independent provider of global services to the life sciences industry.

When an Alzheimer's programme hit a wall after two negative Phase III trials, EVERSANA called on Niche to make sense of.

read more

Funxional Therapeutics Ltd

Regulatory Affairs

Providing a broad range of services, as a trusted CRO to help Funxional realise its clinical vision

The clinical evidence Niche helped generate for Funxional's novel anti-inflammatory compound FX125L proved compelling.

read more

HOOKIPA Pharma

Regulatory Affairs

A small but ambitious company with a pioneering vision for their arenavirus platform

Niche prepared the full regulatory package for HOOKIPA's groundbreaking arenavirus immunotherapy platform, enabling the.

read more

iOnctura

Regulatory Affairs

Evolving study designs and managing complex data outputs to present a comprehensive regulatory package

What began as a CSR writing request grew into a broad regulatory partnership, with Niche guiding iOnctura's roginolisib.

read more

Nanomerics

Regulatory Affairs

Niche was invited to provide support for the development of the regulatory documentation for OC134, a reformulation of tacrolimus

Regulatory documentation, ILAP designation and a robust clinical protocol for the Sunlight Trial — Niche helped.

read more

Thromboserin

Regulatory Affairs

Supporting a biotechnology company dedicated to advancing the treatment of thrombotic diseases, particularly in the areas of blood clotting and related disorders.

Working from poor quality hard copy source materials, Niche rescued and rebuilt Thromboserin's Investigator's Brochure.

read more

VectivBio

Regulatory Affairs

Services were tailored to meet the differing requirements of the regulatory pathway, including providing various study documents and updates.

From Phase I protocols to a full Marketing Authorisation Application, Niche was VectivBio's embedded regulatory writing.

read more

Get our latest news and publications

Sign up to our news letter

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility